A detailed history of Primecap Management CO transactions in Xencor Inc stock. As of the latest transaction made, Primecap Management CO holds 9,137,195 shares of XNCR stock, worth $222 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares
9,137,195
Previous 9,116,202 0.23%
Holding current value
$222 Million
Previous $173 Million 6.48%
% of portfolio
0.14%
Previous 0.13%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$15.7 - $21.65 $329,590 - $454,498
20,993 Added 0.23%
9,137,195 $184 Million
Q2 2024

Aug 09, 2024

BUY
$18.21 - $24.5 $464,263 - $624,627
25,495 Added 0.28%
9,116,202 $173 Million
Q1 2024

May 13, 2024

BUY
$18.65 - $26.52 $3.53 Million - $5.01 Million
189,100 Added 2.12%
9,090,707 $201 Million
Q4 2023

Feb 09, 2024

BUY
$16.53 - $21.42 $11.9 Million - $15.4 Million
717,401 Added 8.77%
8,901,607 $189 Million
Q3 2023

Nov 13, 2023

BUY
$20.08 - $25.39 $8.7 Million - $11 Million
433,354 Added 5.59%
8,184,206 $165 Million
Q2 2023

Aug 11, 2023

BUY
$24.77 - $29.9 $4.66 Million - $5.62 Million
188,033 Added 2.49%
7,750,852 $194 Million
Q1 2023

May 15, 2023

BUY
$25.95 - $36.95 $34.9 Million - $49.7 Million
1,345,916 Added 21.65%
7,562,819 $211 Million
Q4 2022

Feb 13, 2023

BUY
$24.79 - $30.86 $13.1 Million - $16.3 Million
526,672 Added 9.26%
6,216,903 $162 Million
Q3 2022

Nov 14, 2022

BUY
$24.62 - $32.44 $22 Million - $29 Million
895,179 Added 18.67%
5,690,231 $148 Million
Q2 2022

Aug 11, 2022

SELL
$19.74 - $29.01 $2.89 Million - $4.25 Million
-146,560 Reduced 2.97%
4,795,052 $131 Million
Q1 2022

May 11, 2022

SELL
$26.68 - $41.63 $1.23 Million - $1.92 Million
-46,210 Reduced 0.93%
4,941,612 $132 Million
Q4 2021

Feb 11, 2022

SELL
$33.67 - $43.44 $9.7 Million - $12.5 Million
-288,010 Reduced 5.46%
4,987,822 $200 Million
Q3 2021

Nov 12, 2021

SELL
$30.65 - $35.68 $638,746 - $743,571
-20,840 Reduced 0.39%
5,275,832 $172 Million
Q2 2021

Aug 10, 2021

SELL
$34.33 - $44.68 $550,996 - $717,114
-16,050 Reduced 0.3%
5,296,672 $183 Million
Q1 2021

May 14, 2021

SELL
$40.81 - $53.88 $1.13 Million - $1.49 Million
-27,700 Reduced 0.52%
5,312,722 $229 Million
Q4 2020

Feb 08, 2021

SELL
$36.63 - $47.63 $2.48 Million - $3.23 Million
-67,710 Reduced 1.25%
5,340,422 $233 Million
Q3 2020

Nov 13, 2020

SELL
$30.09 - $43.02 $3.63 Million - $5.19 Million
-120,740 Reduced 2.18%
5,408,132 $210 Million
Q2 2020

Aug 13, 2020

SELL
$27.76 - $33.42 $4.76 Million - $5.73 Million
-171,500 Reduced 3.01%
5,528,872 $179 Million
Q1 2020

May 14, 2020

SELL
$20.69 - $37.79 $16.7 Million - $30.5 Million
-806,941 Reduced 12.4%
5,700,372 $170 Million
Q4 2019

Feb 14, 2020

SELL
$32.75 - $41.43 $15.9 Million - $20.1 Million
-484,898 Reduced 6.93%
6,507,313 $224 Million
Q3 2019

Nov 13, 2019

SELL
$33.73 - $46.27 $15.5 Million - $21.3 Million
-460,372 Reduced 6.18%
6,992,211 $236 Million
Q2 2019

Aug 14, 2019

SELL
$29.6 - $40.93 $1.52 Million - $2.1 Million
-51,300 Reduced 0.68%
7,452,583 $305 Million
Q1 2019

May 14, 2019

SELL
$27.85 - $38.09 $3.04 Million - $4.16 Million
-109,100 Reduced 1.43%
7,503,883 $233 Million
Q4 2018

Feb 12, 2019

SELL
$32.39 - $42.05 $283,736 - $368,358
-8,760 Reduced 0.11%
7,612,983 $275 Million
Q3 2018

Nov 13, 2018

BUY
$35.69 - $47.65 $1.96 Million - $2.61 Million
54,800 Added 0.72%
7,621,743 $297 Million
Q2 2018

Aug 13, 2018

BUY
$28.41 - $42.41 $2.59 Million - $3.87 Million
91,300 Added 1.22%
7,566,943 $280 Million
Q1 2018

May 14, 2018

BUY
$21.18 - $33.78 $27.9 Million - $44.5 Million
1,317,400 Added 21.39%
7,475,643 $224 Million
Q4 2017

Feb 13, 2018

BUY
$19.29 - $24.83 $526,617 - $677,859
27,300 Added 0.45%
6,158,243 $135 Million
Q3 2017

Nov 13, 2017

BUY
$19.61 - $23.35 $120 Million - $143 Million
6,130,943
6,130,943 $141 Million

Others Institutions Holding XNCR

About Xencor Inc


  • Ticker XNCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,698,100
  • Market Cap $1.45B
  • Description
  • Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...
More about XNCR
Track This Portfolio

Track Primecap Management CO Portfolio

Follow Primecap Management CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Primecap Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Primecap Management CO with notifications on news.